![BioLoomics](https://www.impactnews-wire.com/wp-content/uploads/blob-7ef54e7.png)
BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
Former CSO of Trilo Therapeutics and Research Fellow at AbbVie joins to lead BioLoomics’ pipeline and combine lysosome targeting antibodies with ADCs BOULDER, Colo. – BioLoomics, a biotechnology company that targets peptide-antibody chimeras to specific compartments inside of diseased cells, announced today that Kurt Gish, Ph.D., has joined as the Chief Scientific Officer. Dr Gish will focus on building the company’s pipeline of lysosomal targeting … Continue reading BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs